Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Michel DuvalDaniel Weisdorf

Abstract

Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT). However, HSCT when a patient is not in complete remission (CR) is of uncertain benefit. We hypothesized that pretransplantation variables may define subgroups that have a better prognosis. Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research. The median follow-up of survivors was 61 months. We performed multivariate analysis of pretransplantation variables and developed a predictive scoring system for survival. The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL). For AML, five adverse pretransplantation variables significantly influenced survival: first CR duration less than 6 months, circulating blasts, donor other than HLA-identical sibling, Karnofsky or Lansky score less than 90, and poor-risk cytogenetics. For ALL, survival was worse with the following: first refractory or ...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K T GodderP J Henslee-Downey
Feb 1, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Raymond WongSergio Giralt
Oct 28, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Edwin P AlyeaRobert J Soiffer
Jan 24, 2007·Biometrical Journal. Biometrische Zeitschrift·Thomas A Gerds, Martin Schumacher
Mar 10, 2007·Statistics in Medicine·John P KleinPer Kragh Andersen
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfJohn Klein

❮ Previous
Next ❯

Citations

Oct 1, 2011·Current Treatment Options in Oncology·Rob SellarHillard M Lazarus
Jul 1, 1995·Parasitology Today·G MilonJ A Louis
May 4, 2013·The Lancet Oncology·Deepa Bhojwani, Ching-Hon Pui
Jan 10, 2012·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Feb 7, 2013·Current Opinion in Hematology·Hongtao LiuMichael R Bishop
Feb 7, 2013·Current Opinion in Hematology·Timothy Kubal, Jeffrey E Lancet
Dec 10, 2013·Hematology·Charles Craddock
Jan 29, 2013·Hematology Reports·Natasha AliNehal Masood
Jun 17, 2014·Bone Marrow Transplantation·M A PulsipherK R Schultz
Dec 3, 2014·Hematology/oncology Clinics of North America·David I MarksRohini Radia
Oct 8, 2011·Current Hematologic Malignancy Reports·E J Feldman, Usama Gergis
Aug 23, 2011·Leukemia & Lymphoma·Satoshi Nishiwaki, Koichi Miyamura
Nov 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sarita Rani JaiswalSuparno Chakrabarti
Feb 14, 2015·European Journal of Haematology·Petra RollHans-Peter Tony
Dec 1, 2011·Best Practice & Research. Clinical Haematology·Daniel Weisdorf
Sep 13, 2012·British Journal of Haematology·Jeffrey E Rubnitz, Hiroto Inaba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.